A mu opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients

Psychopharmacology

Volumn 201, Issue 4, 2009, Pages 611-618

  Kim, Sung Gon ^a   Kim, Cheol Min ^b   Choi, Sam Wook ^c   Jae, Young Myo ^d   Lee, Hae Gook ^e   Son, Bong Ki ^f   Kim, Jeong Gee ^g   Choi, Young Sung ^h   Kim, Han Oh ⁱ   Kim, Seong Yeon ^j   Oslin, David W ^k  

^a Pusan National University School of Medicine   (South Korea)

^b Haein Hospital   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Bong Seng Memorial Hospital   (South Korea)

^e The Catholic University of Korea   (South Korea)

^f Hallym University Medical Center   (South Korea)

^g Maryknoll Hospital   (South Korea)

^h St Andrew's Neuropsychiatric Hospital   (South Korea)

ⁱ Keyo Hospital   (South Korea)

^j Dong A University   (South Korea)

^k UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

Korean alcohol dependent; Mu opioid receptor; Naltrexone; Polymorphism

Indexed keywords

ASPARAGINE; ASPARTIC ACID; MU OPIATE RECEPTOR; NALTREXONE; NARCOTIC ANTAGONIST;

ADULT; ALCOHOLISM; ALLELISM; ARTICLE; ASIAN; COGNITIVE THERAPY; DNA POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SOUTH KOREA; TREATMENT RESPONSE; ALCOHOL ABSTINENCE; ALLELE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENETIC POLYMORPHISM; GENETICS; KOREA; MIDDLE AGED; PROSPECTIVE STUDY; RECURRENT DISEASE;

ADULT; ALCOHOLISM; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; COGNITIVE THERAPY; FEMALE; HUMANS; KOREA; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RECEPTORS, OPIOID, MU; RECURRENCE; TEMPERANCE;

EID: 57049180262     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-008-1330-5     Document Type: Article

References (47)

1. American Psychiatric Association. DSM-IV (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Press, Washington, DC
2. RF Anton DH Moak PK Latham LR Waid RJ Malcolm JK Dias JS Roberts 2001 Posttreatment results of combining naltrexone with cognitive-behavior therapy for the treatment for alcoholism J Clin Psychopharmacol 21 72 77
3. RF Anton G Oroszi S O'Malley D Couper R Swift H Pettinati D Goldman 2008 An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study Arch Gen Psychiatry 65 132 133
4. AW Bergen J Kokoszka R Peterson JC Long M Virkkunen M Linnoila D Goldman 1997 Mu opioid receptor gene variants: lack of associated with alcohol dependence Mol Psychiatry 2 490 494
5. C Bond KS LaForge M Tian D Melia S Zhang L Borg J Gong J Schluger JA Strong SM Leal JA Tischfield MJ Kreek L Yu 1998 Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction Proc Natl Acad Sci USA 95 9608 9613
6. J Chick R Anton K Checinski R Croop DC Drummond R Farmer D Labriola J Marshall J Moncrieff MY Morgan T Peters B Ritson 2000 A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse Alcohol Alcohol 35 587 593
7. WY Chou LC Yang HF Lu JY Ko CH Wang SH Lin TH Lee A Concejero CJ Hsu 2006 Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty Acta Anaesthesiol Scand 50 787 792
8. De Witte (1996) The role of neurotransmitters in alcohol dependence: animal research.31(Suppl 1):13-16
9. FM Filbey L Ray A Smolen ED Claus A Audette KE Hutchison 2008 Differential neuronal response to alcohol priming and alcohol taste cues is associated with DRD4 VNTR and OPRM1 genotypes Alcohol Clin Exp Res 32 1113 1123
10. J Gelernter R Gueorguieva HR Kranzler H Zhang J Cramer R Rosenheck JH Krystal 2007 Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study Alcohol Clin Exp Res 31 555 563
11. J Gelernter H Kranzler J Cubells 1999 Genetics of two mu opioid receptor gene (OPRM1) exon 1 polymorphisms: population studies, and allele frequencies in alcohol- and drug-dependence subjects Mol Psychiatry 4 476 483
12. C Gianoulakis 1996 Implications of endogenous opioids and dopamine in alcoholism: human and basic science studies Alcohol Alcohol 31 Suppl 1 33 42
13. CA Hernandez-Avila G Wand X Luo J Gelernter HR Kranzler 2003 Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1) Am J Med Genet B Neuropsychiatr Genet 118 60 65
14. SG Kim CM Kim DH Kang YJ Kim WT Byun SY Kim JM Park MJ Kim DW Oslin 2004 Association of functional opioid receptor genotypes with alcohol dependence in Koreans Alcohol Clin Exp Res 28 986 990
15. AC King JR Volpicelli A Frazer CP O'Brien 1997 Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence Psychopharmacology 129 15 22
16. P Klepstad TT Rakvag S Kaasa M Holthe O Dale PC Borchgrevink C Baar T Vikan HE Krokan F Skorpen 2004 The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease Acta Anaesthesiol Scand 48 1232 1239
17. H Kranzler V Modesto-Lowe J Van Kirk 2000 Naltrexone vs. nefazadone for treatment of alcohol dependence. A placebo-controlled trial Neuropsychopharmacology 22 493 503
18. JH Krystal JA Cramer WF Krol GF Kirk RA Rosenheck 2001 Veterans Affairs Naltrexone Cooperative Study 425 Group. Naltrexone in the treatment of alcohol dependence N Engl J Med 345 1734 1739
19. DK Lahiri B Schnabel 1993 DNA isolation by a rapid method from human blood samples: effects of MgCl2, EDTA, storage time, and temperature on DNA yield and quality Biochem Genet 31 321 328
20. C Lerman EP Wileyto F Patterson M Rukstalis J Audrain-McGovern S Restine PG Shields V Kaufmann D Redden N Benowitz WH Berrettini 2003 The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial Pharmacogenomics J 4 184 192
21. J Lotsch C Skarke S Grosch J Darimont H Schmidt G Geisslinger 2002 The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine Pharmacogenetics 12 3 9
22. J Lotsch B Stuck T Hummel 2006 The human mu-opioid receptor gene polymorphism 118A > G decreases cortical activation in response to specific nociceptive stimulation Behav Neurosci 120 1218 1224
23. JR Monterosso BA Flannery HM Pettinati DW Oslin M Rukstalis CP O'Brien JR Volpicelli 2001 Predicting treatment response to naltrexone: the influence of craving and family history Am J Addict 10 258 269
24. PM Monti DJ Rohsenow RM Swift SB Gulliver SM Colby TI Mueller RA Brown A Gordon DB Abrams RS Niaura MK Asher 2001 Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes Alcohol Clin Exp Res 25 1634 1647
25. PL Morris M Hopwood G Whelan J Gardiner E Drummond 2001 Naltrexone for alcohol dependence: a randomized controlled trial Addiction 96 1565 1573
26. MR Munafo KM Elliot MF Murphy RT Walton EC Johnstone 2007 Association of the mu-opioid receptor gene with smoking cessation Pharmacogenomics J 7 353 361
27. Murray C, Lopez AD (1996) The global burden of disease: a comprehensive assessment of mortality and disability from disease, injuries, and risk factors in 1990 and projected to 2020. Harvard University Press, Boston
28. BG Oertel R Schmidt A Schneider G Geisslinger J Lotsch 2006 The mu-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers Pharmacogenet Genomics 16 625 636
29. SS O'Malley AJ Jaffe G Chang RS Schottenfeld RE Meyer B Rounsaville 1992 Naltrexone and coping skills therapy for alcohol dependence: a controlled study Arch Gen Psychiatry 49 881 887
30. W Ooteman MW Koeter R Verheul GM Schippers W van den Brink 2007 The effect of naltrexone and acamprosate on cue-induced craving, autonomic nervous system and neuroendocrine reactions to alcohol-related cues in alcoholics Eur Neuropsychopharmacol 17 558 666
31. D Oslin JG Liberto J O'Brein S Krois J Norbeck 1997 Naltrexone as an adjunctive treatment for older patients with alcohol dependence Am J Geriatr Psychiatry 5 324 332
32. DW Oslin W Berrettini HR Kranzler H Pettinati J Gelernter JR Volpicelli CP O'Brien 2003 A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol dependent patients Neuropsychopharmaclolgy 28 1546 1552
33. VA Patel LA Pohorecky 1989 Acute and chronic ethanol treatment on beta-endorphin and catecholamine levels Alcohol 6 59 63
34. LA Ray KE Hutchison 2004 A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans Alcohol Clin Exp Res 28 1789 1795
35. LA Ray KE Hutchison 2007 Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study Arch Gen Psychiatry 64 1069 1077
36. R Ray C Jepson F Patterson A Strasser M Rukstalis K Perkins KG Lynch S O'Malley WH Berrettini C Lerman 2006 Association of OPRM1 A118G variant with the relative reinforcing value of nicotine Psychopharmacology 188 355 363
37. DJ Rohsenow R Miranda Jr JE McGeary PM Monti 2007 Family history and antisocial traits moderate naltrexone's effects on heavy drinking in alcoholics Exp Clin Psychopharmacol 15 272 281
38. T Sander N Gscheidel B Wendel J Samochowiec M Smolka H Rommelspacher LG Schmialt MR Hoehe 1998 Human mu-opioid receptor variation and alcohol dependence Alcohol Clin Exp Res 22 2108 2110
39. E van den Wildenberg RW Wiers J Dessers RG Janssen EH Lambrichs HJ Smeets GJ van Breukelen 2007 A functional polymorphism of the mu-opioid receptor gene (OPRM1) influences cue-induced craving for alcohol in male heavy drinkers Alcohol Clin Exp Res 31 1 10
40. Volpicelli JR, O'Brein CP, Alterman AI, Hayashida M (1990) Naltrexone and the treatment of alcohol dependence: initial observations. In: Reid LD (ed) Opioids, bulimia and alcohol abuse & addiction. Springer, New York, pp 195-214
41. JR Volpicelli AI Alterman M Hayashida CP O'Brien 1992 Naltrexone in the treatment of alcohol dependence Arch Gen Psychiatry 49 876 880
42. JR Volpicelli NT Watson AC King CE Sherman CP O'Brien 1995 Effect of naltrexone on alcohol 'high' in alcoholics Am J Psychiatry 152 613 615
43. GS Wand M McCaul X Yang J Reynolds D Gotjen S Lee A Ali 2002 The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade Neuropsychopharmacology 26 106 114
44. PS Widdowson RB Holman 1992 Ethanol-induced increase in endogenous dopamine release may involve endogenous opiates J Neurochem 59 157 163
45. PL Wood 1982 Multiple opiate receptors: support for unique mu, delta and kappa sites Neuropharmacology 21 487 497
46. Y Zhang D Wang AD Johnson AC Papp W Sadee 2005 Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G J Biol Chem 280 32618 32624
47. D Zhang C Shao M Shao P Yan Y Wang Y Liu W Liu T Lin Y Xie Y Zha D Lu Y Li L Jin 2007 Effect of mu-opioid receptor gene polymorphisms on heroin-induced subjective responses in a Chinese population Bio Psychiatry 61 1244 1251